|
gptkbp:instanceOf
|
gptkb:drug
gptkb:biologic_medication
|
|
gptkbp:activeIngredient
|
gptkb:adalimumab
|
|
gptkbp:approvalYear
|
2018
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AB04
|
|
gptkbp:biosimilar
|
gptkb:Humira
|
|
gptkbp:brand
|
gptkb:Hyrimoz
|
|
gptkbp:countryOfOperation
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:genericName
|
adalimumab-adaz
|
|
gptkbp:indication
|
gptkb:juvenile_idiopathic_arthritis
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
ankylosing spondylitis
plaque psoriasis
hidradenitis suppurativa
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Sandoz
|
|
gptkbp:mechanismOfAction
|
TNF inhibitor
|
|
gptkbp:pregnancyCategory
|
Consult physician
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:bfsParent
|
gptkb:adalimumab
gptkb:adalimumab_(Humira)
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Hyrimoz
|